NCT05472428View on ClinicalTrials.gov

Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

December 25, 2020

Study Completion Date

August 31, 2021

Conditions
Stem Cell Infusion
Interventions
COMBINATION_PRODUCT

Autologous bone marrow mononuclear cell transplantation

Transplantation of Autologous Bone Marrow Mononuclear cells

Trial Locations (1)

100000

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors
collaborator

Vinmec Health Care System (Vingroup Joint Stock Company)

UNKNOWN

lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER

NCT05472428 - Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida | Biotech Hunter | Biotech Hunter